in the development of a transportable, artificial blood circulation system - similar to organ transplants - that keeps severed limbs viable outside the body for a longer period of time and optimally prepares

Department". Finally, we look "Beyond Dialysis" at perspectives in nephrology, nephropathology and transplantation. We would like to thank all contributors and look forward to exchanging ideas with you in Hanover

hypertension (PAH), a lung transplant is sometimes the only remaining treatment option. However, there is a substantial risk of various complications following lung transplantation. In addition to direct toxic [...] of COVID-19 disease and its late effects as well as the pathophysiology of changes after lung transplantation. The Lung Research Group is characterized by a national and international network with numerous [...] median 5-year survival is about 30%. A curative therapy is not yet available, leaving only lung transplantation as a last resort in the final stage of the disease. Histomorphological signs of advanced PAH

(2015): Striatal transplantation of human dopaminergic neurons differentiated from induced pluripotent stem cells derived from umbilical cord blood using lentiviral reprogramming. Cell Transplant. 2015;24(1 [...] Functional Restoration of Human Fetal Ventral Mesencephalon FollowingTransplantation in a Rat Model of Parkinson's Disease. Cell Transplant; DOI: 10.3727/096368912X654984 Klein A, Sacrey LA, Whishaw IQ, Dunnett [...] nigral and striatal cell transplantation. Prog Brain Res; 200:279-301 Trueman RC, Klein A, Lindgren HS, Lelos MJ, Dunnett SB. (2012) Repair of the CNS Using Endogenous and Transplanted Neural Stem Cells. Curr

research focuses on the MHH's priority areas: inflammation, infection and immunology, as well as transplantation, tissue regeneration and implants, as well as oncology.

Unified Biobank, and Professor Dr Axel Haverich, Director of the Clinic for Cardiac, Thoracic, Transplantation and Vascular Surgery. According to the evaluation, Harvard University in Boston (USA) is the

that include a Bruton's tyrosine kinase (BTK) inhibitor) B-ALL (up to 25 years: relapse after transplantation, or second or later relapse; from 26 years: relapsed or refractory B-cell precursor ALL) Multiple

provided: Priv.-Doz. Dr. med. Linda Feldbrügge, Clinical Department of General, Visceral and Transplantation Medicine , with the project "Purinergic immune regulation, mediated by CD39, in the tumor immune

Bavendiek Prof. Dr. med. J. Bauersachs Prof. Dr. med. Genot Beutel (Haematology, Stem Cell Transplantation)

Laboratories for Biotechnology and Artificial Organs (LEBAO) and the Department of Cardiothoracic, Transplantation and Vascular Surgery (HTTG) at Hannover Medical School (MHH) with the support of Gaby Froriep